Panoramica

Idoneità

Dettagli del Disegno

Bracci e Interventi

Misure di Esito

Siti dello Studio

Fonte: NCT04961996

Attivo, non recluta

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

Interventistico

Fase 3

Avera Cancer Institute

Sponsor: Roche

Ultimo Aggiornamento: 12 agosto 2025
Avviso - Le informazioni provengono da registri pubblici e potrebbero non riflettere i cambiamenti in tempo reale presso il centro locale.

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

In addition, an open-label exploratory substudy will explore the safety and efficacy of giredestrant in combination with abemaciclib in a subset of the primary study population.

Categoria di Trattamento

Terapia Ormonale, Altri Farmaci, Terapia Mirata

Mutazioni richieste

ER, HER2

Studio Iniziato

27 agosto 2021

Ultimo Aggiornamento dello Sponsor

12 agosto 2025

Completamento Stimato

31 marzo 2026

Contatto dello studio

Nome:Reference Study ID Number: GO42784 https://forpatients.roche.com/

Email:global-roche-genentech-trials@gene.com

Telefono:888-662-6728 (U.S. Only)

Idoneità

Criteri di Inclusione

* Documented estrogen receptor (ER)-positive and HER2-negative breast tumor, as assessed locally on a primary disease specimen

* Participants who have multicentric (the presence of two of more tumor foci within different quadrants of the same breast) and/or multifocal (the presence of two or more tumor foci within a single quadrant of the breast) breast cancer are also eligible if all examined tumors meet pathologic criteria for ER positivity and HER2 negativity

* Participants must have undergone definitive surgery of their primary breast tumor(s) and axillary lymph nodes (axillary lymph node dissection [ALND] and/or sentinel lymph node biopsy [SLNB])

* Participants who received or will be receiving adjuvant chemotherapy must have completed adjuvant chemotherapy prior to randomization. Participants may also have received neoadjuvant chemotherapy. A washout period of at least 21 days is required between last adjuvant chemotherapy dose and randomization.

* Resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to NCI CTCAE v5.0 Grade 1 or better (except alopecia, Grade ≤2 peripheral neuropathy, arthralgia or other toxicities not considered a safety risk for the participant per the investigator's judgment)

* Participants have received (neo)adjuvant chemotherapy and/or had surgery and had no prior endocrine therapy are eligible, provided that they are enrolled within 12 months following definitive breast cancer surgery

* Participants who have confirmed availability of an untreated primary breast tumor tissue specimen suitable for biomarker testing (i.e., representative archived formalin-fixed, paraffin-embedded [FFPE] tissue block [preferred] or 15-20 slides containing unstained, freshly cut, serial sections), with associated de-identified pathology report is required. Although 15-20 slides are preferred, if only 10-14 slides are available, the individual may still be eligible for the study.

* Participants with node-positive and node-negative disease are eligible provided they meet additional risk criteria as defined in the protocol

* Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1, or 2

* Able and willing to swallow, retain, and absorb oral medication

* Adequate organ function

To be eligible for substudy participation, in addition to meeting the inclusion criteria in the primary protocol, participants must also meet the following modified criteria:

- Patients who received adjuvant radiotherapy must have completed radiotherapy prior to enrollment, and patients must have recovered (to Grade ≤1) from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and enrollment.

Criteri di Esclusione

* Pregnant or breastfeeding, or intending to become pregnant during the study or within 10 days after the final dose of giredestrant, or within the time period specified per local prescribing guidelines after the final dose of the endocrine therapy of physician's choice

* Received treatment with investigational therapy within 28 days prior to initiation of study treatment or is currently enrolled in any other type of medical research judged by the sponsor not to be scientifically or medically compatible with this study

* Receiving or planning to receive a CDK4/6 inhibitor as (neo)adjuvant therapy. A short course of up to 12 weeks of neoadjuvant or adjuvant treatment with CDK4/6 inhibitor therapy prior to randomization is allowed.

* Active cardiac disease or history of cardiac dysfunction

* Diagnosed with Stage IV breast cancer

* A history of any prior (ipsilateral and/or contralateral) invasive breast cancer or ductal carcinoma in situ (DCIS). Participants with a history of contralateral DCIS treated by only local regional therapy at any time may be eligible.

* A history of any other malignancy within 3 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, or Stage I uterine cancer

* Any prior endocrine treatment with selective ER modulators (e.g., tamoxifen), degraders, or aromatase inhibitors. A short course of neoadjuvant or adjuvant endocrine therapy (up to 12 weeks) is allowed.

* Clinically significant liver disease consistent with Child-Pugh Class B or C, including active hepatitis (e.g., hepatitis B virus [HBV] or hepatitis C virus [HCV]), current alcohol abuse, cirrhosis, or positive test for viral hepatitis

* Treatment with strong CYP3A4 inhibitors or inducers within 14 days or 5 drug elimination half-lives (whichever is longer) prior to initiation of study treatment

* Known allergy or hypersensitivity to any of the study drugs or any of their excipients

* Pre- and perimenopausal participants or male participants who have a known hypersensitivity to LHRH agonists

* A documented history of hemorrhagic diathesis, coagulopathy, or thromboembolism

* Renal dysfunction that requires dialysis

* A major surgical procedure unrelated to breast cancer within 28 days prior to randomization

* A serious infection requiring oral or IV antibiotics within 14 days prior to screening or other clinically significant infection (e.g., COVID-19) within 14 days prior to screening

* Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes an individual's safe participation in and completion of the study

* Unable or unwilling to comply with the requirements of the protocol in the opinion of the investigator

Potential participants are excluded from the substudy if any criteria from the primary study or the following criteria apply:

* Prior participation in the GO42784 primary study

* Received a CDK4/6i as (neo)adjuvant therapy prior to enrollment

* Treatment with moderate CYP3A inducers, strong CYP3A inducers or strong CYP3A inhibitors within 14 days or 5 drug elimination half-lives (whichever is longer) prior to initiation of study treatment

Pensi che questo studio appaia erroneamente?

Dettagli del Disegno

AllocazioneRandomized

Modello di InterventoParallel Assignment

MascheramentoNone (Open Label)

Numero da Arruolare4200

Bracci e Interventi

Bracci

Interventi

Tipo: Experimental

Descrizione:

Interventi:

Giredestrant
Endocrine Therapy of Physician's Choice
LHRH Agonist
Abemaciclib

Misure di Esito

Misure di Esito Primarie

Invasive Disease-Free Survival (IDFS), Excluding Second Primary Non-Breast CancersFrom randomization to first occurrence of an IDFS event (up to 10 years)

Misure di Esito Secondarie

Overall SurvivalFrom randomization to death from any cause (up to 10 years)

Invasive Disease-Free Survival (IDFS), Including Second Primary Non-Breast CancersFrom randomization to first occurrence of an IDFS event (up to 10 years)

Disease-Free Survival (DFS)From randomization to first occurrence of a DFS event (up to 10 years)

Distant Recurrence-Free Interval (DRFI)From randomization to first occurrence of a DFRI event (up to 10 years)

Locoregional Recurrence-Free Interval (LRRFI)From randomization to first occurrence of a LRRFI event (up to 10 years)

Incidence and Severity of Adverse Events, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE v5.0)From start of treatment until 28 days after the final dose of study treatment (up to 5 years)

Mean Physical Functioning Scale Score at Specified Timepoints, Assessed Using the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)Baseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)

Change from Baseline in the Mean Physical Functioning Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30Baseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)

Mean Role Functioning Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30Baseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)

Change from Baseline in the Mean Role Functioning Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30Baseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)

Mean Global Health Status/Quality of Life (QoL) Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30Baseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)

Change from Baseline in the Mean Global Health Status/Quality of Life (QoL) Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30Baseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)

Change from Baseline in the EQ 5D-5L Index-Based Score at Specified TimepointsBaseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)

Change from Baseline in the EQ 5D-5L Visual Analogue Scale (VAS) Score at Specified TimepointsBaseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)

Plasma Concentrations of Giredestrant at Specified TimepointsPredose and 3-4 hours postdose on Day 1 of Cycles 1 and 2, and predose on Day 1 of Cycles 3 and 6 (1 cycle is 28 days)

Substudy: Incidence of Grade ≥3 Adverse Events with Giredestrant in Combination with AbemaciclibFrom first dose of study treatment until 28 days after the last dose of treatment with the combination of giredestrant and abemaciclib or until the end of Year 2, whichever occurs first (up to 2 years)

Substudy: Incidence and Severity of Adverse Events with Giredestrant in Combination with Abemaciclib, with Severity Determined According to NCI-CTCAE v5.0From first dose of study treatment until 28 days after the last dose of treatment with the combination of giredestrant and abemaciclib or until the end of Year 2, whichever occurs first (up to 2 years)

Aggiungi studio ai preferiti

Condividi Studio

Scarica lo studio

Pensi che questo studio appaia erroneamente?

Segnala Studio

Scarica lo studio

Siti dello Studio

Questo studio ha 105 siti

Avera Cancer Institute

Sioux Falls, South Dakota, US

In fase di reclutamento

Sioux Falls, South Dakota, 57105 US

Avera Cancer Institute

In fase di reclutamento

Seattle, Washington, 98104 US

Swedish Cancer Institute

In fase di reclutamento

Cedar Rapids, Iowa, 52403 US

Oncology Associates at Mercy Medical Center

In fase di reclutamento

Brighton, South East, BN2 5BE GB

Royal Sussex County Hospital

In fase di reclutamento

West Reading, Pennsylvania, 19611 US

Reading Hospital

In fase di reclutamento

Miami Beach, Florida, 33140 US

Mount Sinai Comprehensive Cancer Center

In fase di reclutamento

Cádiz, Cádiz, 11009 ES

Hospital Universitario Puerta del Mar

In fase di reclutamento

Vallejo, California, 94589 US

Kaiser Permanente - Vallejo

In fase di reclutamento

Lexington, Kentucky, 40536 US

University of Kentucky

In fase di reclutamento

Canton, Ohio, 44710 US

Aultman Hospital

In fase di reclutamento

Cleveland, Ohio, 44195 US

Cleveland Clinic

In fase di reclutamento

Villejuif, 94805 FR

Institut Gustave Roussy

In fase di reclutamento

Joliet, Illinois, 60435 US

Joliet Oncology Hematology Associates, Ltd.

In fase di reclutamento

Leuven, 3000 BE

UZ Leuven

In fase di reclutamento

New Orleans, Louisiana, 70112 US

University Medical Center New Orleans

In fase di reclutamento

Raleigh, North Carolina, 27607 US

Rex Cancer Center

In fase di reclutamento

Paris, 75908 FR

Hôpital Européen Georges Pompidou

In fase di reclutamento

Lubbock, Texas, 79410 US

Joe Arrington Cancer Research & Treatment Center

In fase di reclutamento

Palo Alto, California, 94304 US

Stanford University Medical Center

In fase di reclutamento

Plainfield, Illinois, 60585 US

Edward Cancer Center Plainfield

In fase di reclutamento

Long Beach, California, 90806 US

Long Beach Memorial Medical Center

In fase di reclutamento

New Brunswick, New Jersey, 08901 US

Rutgers Cancer Institute of New Jersey

In fase di reclutamento

Los Angeles, California, 90095 US

UCLA Hematology/Oncology

In fase di reclutamento

Charlotte, North Carolina, 28204 US

Levine Cancer Institute

In fase di reclutamento

Pittsburgh, Pennsylvania, 15213 US

Magee Womens Hospital

In fase di reclutamento

Providence, Rhode Island, 02905 US

Women & Infants Hospital

In fase di reclutamento

Gainesville, Florida, 32608 US

University of Florida

In fase di reclutamento

Paris, 75475 FR

Hopital Saint Louis

In fase di reclutamento

Jacksonville, Florida, 32207 US

Baptist - MD Anderson Cancer Center

In fase di reclutamento

Morgantown, West Virginia, 26056 US

West Virginia University Hospitals Inc

In fase di reclutamento

Richmond, Virginia, 23298 US

Virginia Commonwealth University - Massey Cancer Center

In fase di reclutamento

Cleveland, Ohio, 44106 US

University Hospitals Cleveland Medical Center

In fase di reclutamento

San Diego, California, 92120 US

Kaiser Permanente - San Diego

In fase di reclutamento

Houston, Texas, 77030 US

Houston Methodist Cancer Center

In fase di reclutamento

Montreal, Quebec, H3T 1E2 CA

Sir Mortimer B Davis Jewish General Hospital

In fase di reclutamento

Chicago, Illinois, 60637 US

University of Chicago Hospital

In fase di reclutamento

San Jose, California, 95124 US

Stanford Cancer Center South Bay

In fase di reclutamento

Athens, 11527 GR

Sotiria Chest Hospital of Athens

In fase di reclutamento

Larissa, 412 21 GR

University General Hospital of Larissa

In fase di reclutamento

Patras, 265 00 GR

University General Hospital of Patras

In fase di reclutamento

Thessaloniki, 546 22 GR

Bioclinic Thessaloniki

In fase di reclutamento

Thessaloniki, 564 29 GR

Papageorgiou General Hospital of Thessaloniki

In fase di reclutamento

Lajeado, Rio Grande Do Sul, 95900-000 BR

Hospital Bruno Born

In fase di reclutamento

Hangzhou City, 310016 CN

Sir Run Run Shaw Hospital Zhejiang University

In fase di reclutamento

Ann Arbor, Michigan, 48109 US

University Of Michigan

In fase di reclutamento

Pretoria, 0001 ZA

Wilgers Oncology Centre

In fase di reclutamento

Cape Town, 7700 ZA

Cancercare Rondebosch Oncology

In fase di reclutamento

Milwaukee, Wisconsin, 53226 US

Froedtert and The Medical College of Wisconsin

In fase di reclutamento

Columbus, Ohio, 43212 US

Stefanie Spielman Comprehensive Breast Center

In fase di reclutamento

Hangzhou City, 310009 CN

The Second Affiliated Hospital of Zhejiang University School of Medicine

In fase di reclutamento

Miami, Florida, 33176 US

Miami Cancer Institute of Baptist Health, Inc.

In fase di reclutamento

Orange, California, 92868 US

The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange

In fase di reclutamento

Houston, Texas, 77030 US

Baylor College of Medicine Medical Center

In fase di reclutamento

Kunming, 650118 CN

Yunnan Cancer Hospital

In fase di reclutamento

Stockholm, 11883 SE

Södersjukhuset

In fase di reclutamento

Uppsala, 751 85 SE

Akademiska Sjukhuset

In fase di reclutamento

Strasbourg, 67033 FR

Institut de Cancérologie Strasbourg Europe

In fase di reclutamento

Gera, 07548 DE

SRH Wald-Klinikum Gera

In fase di reclutamento

Montreal, Quebec, H2X 3E4 CA

CHUM

In fase di reclutamento

Cholargos, 155 62 GR

Metropolitan General Hospital

In fase di reclutamento

Orlando, Florida, 32806 US

Orlando Health Cancer Institute

In fase di reclutamento

Linz, 4010 AT

Ordensklinikum Linz GmbH

In fase di reclutamento

Herakleion, 711 10 GR

University General Hospital of Heraklion

In fase di reclutamento

Columbus, Ohio, 43125 US

Columbus NCORP

In fase di reclutamento

Ioannina, 455 00 GR

University General Hospital of Ioannina

In fase di reclutamento

Firenze, Toscana, 50134 IT

Azienda Ospedaliera Universitaria Careggi

In fase di reclutamento

New York, New York, 10016 US

New York University Cancer Cen

In fase di reclutamento

Patras, 264 43 GR

Olympion Clinic

In fase di reclutamento

Hannover, 30177 DE

Gynäkologisch Onkologische Praxis Hannover

In fase di reclutamento

McKinney, Texas, 75071 US

Texas Oncology McKinney

In fase di reclutamento

Bonn, 53111 DE

Lübecker Onkologische Schwerpunktpraxis

In fase di reclutamento

Lübeck, 23562 DE

Facharztpraxis für Gynäkologie und Geburtshilfe PD Dr. med. Christian Kurbacher

In fase di reclutamento

Sundsvall, 851 86 SE

Sundsvalls sjukhus

In fase di reclutamento

Negrar, Veneto, 37024 IT

IRCCS Ospedale Sacro Cuore Don Calabria

In fase di reclutamento

Athens, 115 26 GR

Henry Dunant Hospital

In fase di reclutamento

Athens, 145 64 GR

General Oncology Hospital Kifissias "Oi Agioi Anargyroi"

In fase di reclutamento

Faliro, 185 47 GR

Metropolitan Hospital First Oncology Clinic

In fase di reclutamento

Marousi, 151 23 GR

IASO Obstetrics Gynecology Clinic

In fase di reclutamento

Marousi, 151 25 GR

Medical Center of Athens

In fase di reclutamento

Thessaloniki, 546 39 GR

Interbalkan Medical Center of Thessaloniki

In fase di reclutamento

Thessaloniki, 546 45 GR

Euromedica PPDS

In fase di reclutamento

Stony Brook, New York, 11794 US

Stony Brook Univ Cancer Ctr

In fase di reclutamento

Portland, Oregon, 97227 US

Kaiser Permanente-Northwest Region

In fase di reclutamento

Amiens, 80090 FR

Sas Clinique De L Europe - Amiens

In fase di reclutamento

Savannah, Georgia, 31404 US

Memorial Health University Cancer Center

In fase di reclutamento

Louisville, Kentucky, 40202 US

Norton Cancer Institute - MDC

In fase di reclutamento

Midlothian, Virginia, 23114 US

Bon Secours Mercy Health

In fase di reclutamento

Iowa City, Iowa, 52242-1086 US

University of Iowa

In fase di reclutamento

Chaidari, 124 62 GR

Attikon University General Hospital

In fase di reclutamento

Elmhurst, Illinois, 60126 US

Elmhurst Cancer Center

In fase di reclutamento

Panorama, 552 36 GR

Agios Loucas Clinic SA

In fase di reclutamento

Cumberland, Maryland, 21502 US

UPMC Western Maryland - Schwab Family Cancer Center

In fase di reclutamento

Newport Beach, California, 92663-4121 US

Keck Medicine of USC ? Newport Beach

In fase di reclutamento

Lynchburg, Virginia, 24501 US

Centra Alan B. Pearson Regional Cancer Center

In fase di reclutamento

Puebla, Mexico CITY (federal District), MX

Clínica Integral Internacional de Oncología S de RL de CV

In fase di reclutamento

Towson, Maryland, 21204 US

University of Maryland

In fase di reclutamento

Saint Louis Park, Minnesota, 55426 US

Metro-Minnesota Community Oncology Research Consortium

In fase di reclutamento

Columbia, Missouri, 65203 US

University of Missouri-Columbia

In fase di reclutamento

Winston-Salem, North Carolina, 27157 US

Atrium Health Wake Forest Baptist Medical Center - PPDS

In fase di reclutamento

Harrisburg, Pennsylvania, 17109 US

Pinnacle Health

In fase di reclutamento

Salvador/BA, Bahia, 41820-021 BR

Centro de Oncologia da Bahia

In fase di reclutamento

Montreal, Quebec, H1T 2M4 CA

CIUSSS-de-l?Est-de-l?Île-de-Montréal

In fase di reclutamento

Athens, 115 27 GR

University of Athens, Hematological Clinic,

In fase di reclutamento

Västerås, 721 89 SE

Västmanlands sjukhus Västerås

In fase di reclutamento

São Paulo, 04543-000 BR

Onco Star Sp Oncologia Ltda

Loading Maps...